scPharmaceuticalsは、債務返済とFUROSCIXの商業化のために、Perceptive Advisorsから$125Mの非希薄化融資を確保しています。 scPharmaceuticals secures $125M non-dilutive financing from Perceptive Advisors for debt repayment and FUROSCIX commercialization.

scPharmaceuticals Inc.は,普通株式や事前資金調達ウォラントの保証公開を発表し,保証人は30日以内に15%の追加購入オプションを持つ. scPharmaceuticals Inc. announces an underwritten public offering of common stock or pre-funded warrants, with option for underwriters to buy 15% more within 30 days. 生命科学の投資家であるPerceptive Advisorsから 減水性でない資金調達を 最大125Mドルまで確保した. The company also secures up to $125M non-dilutive financing from Perceptive Advisors, a life-sciences investor. 両取引からの収益は,債務返済とFUROSCIXの継続的な商業化に使用されます. Proceeds from both transactions will be used for debt repayment and ongoing commercialization of FUROSCIX.